www.zerohedge.com BY TYLER DURDEN
Despite repeated warnings from the WHO that emerging nations should be given priority access to the mRNA vaccines produced by Moderna and Pfizer, American authorities are looking at potentially authorizing a second doses for at least some patients as they further consider whether to recommend annual boosters.Â
The planning is still in its early stages, and authorization would ultimately depend on ongoing studies establishing that a fourth dose would shore up people’s molecular defenses, which have waned after their first booster and reduced their risk of symptomatic and severe disease.
Among the issues that need to be resolved, according to WSJ’s source, are whether the second booster dose should be authorized for all adults or particular age groups, and whether it should target the omicron variant specifically, or be formulated differently.
